Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director David A. Socks sold 12,835 shares of the business’s stock in a transaction on Monday, January 11th. The stock was sold at an average price of $34.92, for a total transaction of $448,198.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of NASDAQ:PHAT traded down $0.06 on Wednesday, hitting $36.25. The company had a trading volume of 65,870 shares, compared to its average volume of 122,021. The company has a current ratio of 18.76, a quick ratio of 18.76 and a debt-to-equity ratio of 0.24. The stock has a 50 day moving average price of $40.01 and a 200 day moving average price of $37.28. Phathom Pharmaceuticals, Inc. has a 1-year low of $22.06 and a 1-year high of $64.54. The stock has a market cap of $1.05 billion and a price-to-earnings ratio of -2.59.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.35). Sell-side analysts anticipate that Phathom Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Phathom Pharmaceuticals by 240.2% in the second quarter. Vanguard Group Inc. now owns 699,119 shares of the company’s stock valued at $23,008,000 after acquiring an additional 493,607 shares in the last quarter. State Street Corp grew its stake in shares of Phathom Pharmaceuticals by 0.7% in the third quarter. State Street Corp now owns 214,307 shares of the company’s stock valued at $7,859,000 after acquiring an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Phathom Pharmaceuticals by 1.5% in the third quarter. JPMorgan Chase & Co. now owns 162,595 shares of the company’s stock valued at $5,819,000 after acquiring an additional 2,476 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Phathom Pharmaceuticals by 19.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 81,668 shares of the company’s stock valued at $2,688,000 after acquiring an additional 13,065 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Phathom Pharmaceuticals by 41.0% in the second quarter. Nuveen Asset Management LLC now owns 50,038 shares of the company’s stock valued at $1,647,000 after acquiring an additional 14,546 shares in the last quarter. Institutional investors and hedge funds own 74.54% of the company’s stock.

A number of brokerages recently weighed in on PHAT. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 5th. BidaskClub upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 7th. Needham & Company LLC upped their price objective on shares of Phathom Pharmaceuticals from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, December 15th. Finally, ValuEngine upgraded shares of Phathom Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Phathom Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $42.67.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Recommended Story: Capital Gains

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.